Surrozen, Inc. (SRZNW)

0.0290 0.0000 (0.00%) At close: 04:00PM EDT

Surrozen, Inc.

171 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650 489 9000
https://www.surrozen.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 42

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Craig C. Parker M.B.A.	CEO, President & Director	825.32k	N/A	1962
Mr. Charles Williams	CFO, COO & Corporate Secretary	611.03k	N/A	1980
Dr. Li Yang Ph.D.	Executive Vice President of Research	535.46k	N/A	1969
Dr. K. Christopher Garcia Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Roeland Nusse Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1950
Dr. Calvin Kuo M.D., Ph.D.	Co-Founder & Member of Scientific Advisor	N/A	N/A	N/A
Esther Jhun	Controller	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Corporate Governance

Surrozen, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.